Genome-wide association studies (GWAS) have reproducibly associated variants within introns of FTO with increased risk for obesity and type 2 diabetes (T2D) [1][2][3] . Although the molecular mechanisms linking these noncoding variants with obesity are not immediately obvious, subsequent studies in mice demonstrated that FTO expression levels influence body mass and composition phenotypes 4-6 . However, no direct connection between the obesity-associated variants and FTO expression or function has been made 7-9 . Here we show that the obesity-associated noncoding sequences within FTO are functionally connected, at megabase distances, with the homeobox gene IRX3. The obesity-associated FTO region directly interacts with the promoters of IRX3 as well as FTO in the human, mouse and zebrafish genomes. Furthermore, long-range enhancers within this region recapitulate aspects of IRX3 expression, suggesting that the obesity-associated interval belongs to the regulatory landscape of IRX3. Consistent with this, obesity-associated single nucleotide polymorphisms are associated with expression of IRX3, but not FTO, in human brains. A direct link between IRX3 expression and regulation of body mass and composition is demonstrated by a reduction in body weight of 25 to 30% in Irx3-deficient mice, primarily through the loss of fat mass and increase in basal metabolic rate with browning of white adipose tissue. Finally, hypothalamic expression of a dominantnegative form of Irx3 reproduces the metabolic phenotypes of Irx3deficient mice. Our data suggest that IRX3 is a functional long-range target of obesity-associated variants within FTO and represents a novel determinant of body mass and composition.
Genome-wide association studies (GWAS) have reproducibly associated variants within introns of FTO with increased risk for obesity and type 2 diabetes (T2D) 1-3 . Although the molecular mechanisms linking these noncoding variants with obesity are not immediately obvious, subsequent studies in mice demonstrated that FTO expression levels influence body mass and composition phenotypes 4-6 . However, no direct connection between the obesity-associated variants and FTO expression or function has been made [7] [8] [9] . Here we show that the obesity-associated noncoding sequences within FTO are functionally connected, at megabase distances, with the homeobox gene IRX3. The obesity-associated FTO region directly interacts with the promoters of IRX3 as well as FTO in the human, mouse and zebrafish genomes. Furthermore, long-range enhancers within this region recapitulate aspects of IRX3 expression, suggesting that the obesity-associated interval belongs to the regulatory landscape of IRX3. Consistent with this, obesity-associated single nucleotide polymorphisms are associated with expression of IRX3, but not FTO, in human brains. A direct link between IRX3 expression and regulation of body mass and composition is demonstrated by a reduction in body weight of 25 to 30% in Irx3-deficient mice, primarily through the loss of fat mass and increase in basal metabolic rate with browning of white adipose tissue. Finally, hypothalamic expression of a dominantnegative form of Irx3 reproduces the metabolic phenotypes of Irx3deficient mice. Our data suggest that IRX3 is a functional long-range target of obesity-associated variants within FTO and represents a novel determinant of body mass and composition.
Noncoding variation in single nucleotide polymorphisms (SNPs) within a 47-kilobase (kb) region of high linkage disequilibrium in introns 1 and 2 of FTO remains the strongest genetic association with risk to polygenic obesity in humans 1-4 . Individuals homozygous for risk alleles of the associated SNPs weigh approximately 3 kg more than individuals homozygous for non-risk alleles, underscoring the significant phenotypic impact of these common variants 2 . Multiple follow-up studies directly implicated FTO as a gene controlling body mass and composition. Null Fto alleles in mice result in lean phenotypes, with reciprocal models overexpressing FTO displaying increased body weight 4-6 . However, there is no direct evidence that enhancers within the obesity-associated FTO introns are connected with regulation of FTO expression. Expression quantitative trait locus (eQTL) analyses have systematically failed to show association between the obesity-associated SNPs and FTO expression in human tissues [7] [8] [9] .
To chart directly the cis-regulatory circuitry within the FTO locus, we used circular chromosome conformation capture followed by highthroughput sequencing (4C-seq). We carried out 4C-seq in whole mouse embryos (embryonic day 9.5; E9.5) and in adult (8 weeks) mouse brains, as previous work suggests that brain FTO expression modulates metabolic parameters 6, 10 . We profiled the genomic interactions with promoters of genes located within a 1-megabase (Mb) window around the obesity-associated SNPs (mouse genome build mm9, chromosome 8: 93,725,000-94,725,000), including Fto and Rpgrip1l, and Irx3, a halfmegabase downstream. There was a clear difference in interaction patterns among genes (Fig. 1a ). The Fto promoter chiefly participates in genomic interactions proximal to the gene promoter. Although in mouse embryos these interactions include the obesity-associated intronic region ( Fig. 1b ), no such interactions are detected in adult mouse brains (Extended Data Fig. 1 and Supplementary Table 1 ). In marked contrast, the promoter of Irx3 participates in numerous long-range interactions across a broad genomic region encompassing nearly 2 Mb, including robust interactions with the obesity-associated interval within FTO ( Fig. 1a ). We confirmed these interactions between Irx3 and the Fto obesity-associated region using chromatin conformation capture (3C) in adult mouse brains (Extended Data Fig. 2c ). These data suggest that the obesity-associated interval is likely to be part of the regulatory landscape of Irx3. We next inferred that the long-range interactions between the obesity-associated FTO intron and IRX3 represent a conserved feature in vertebrate genomes. Inspecting the human ENCODE data set, we observe that human breast cancer MCF-7 cells display the same pattern of long-range looping between the obesity-associated interval and IRX3, but not FTO, assayed by chromatin interaction analysis with paired-end tag sequencing (ChIA-PET) (Extended Data Fig. 2a ). This is corroborated further by recent Hi-C (high-throughput 3C) data in human fibroblasts 11 (Extended Data Fig. 2b ). We also observed a similar pattern of chromatin interactions in zebrafish embryos, assayed by 4C-seq (Extended Data Fig. 1c ). Together, these data suggest that the obesity-associated FTO intron is mediating functional interactions with IRX3 in the human, mouse and zebrafish genomes.
After revealing evidence of direct looping between FTO intronic regions and IRX3, we next showed that enhancers within the obesity-associated interval possess functional characteristics compatible with IRX3 expression. We observed that the degree of evolutionary conservation in noncoding sequences of the FTO-IRX locus (chromosome 16: 53,731,249-54,975,288) places it on the top 2% of similarly sized genomic intervals, suggesting the presence of many functional noncoding elements spread over the region (see Methods). More specifically, ENCODE data suggest that the 47-kb obesity-associated interval is fraught with cis-regulatory elements, evidenced by an abundance of enhancer-associated chromatin marks, DNase hypersensitive sites, and transcription-factor binding events across this genomic region ( Fig. 1b ). We tested three human DNA fragments from the 47-kb obesity-associated region for their putative enhancer properties using an in vivo mouse reporter assay. These fragments overlap enhancer-like chromatin marks in multiple cell lines. All three fragments displayed enhancer activity in neonatal (postnatal day 0 (P0)-P1) mice. Interestingly, two of the fragments drove strong reporter gene expression in lungs ( Fig. 1b ). Irx3 is highly expressed during lung development ( Fig. 1b) 12, 13 , whereas Fto expression in lungs is limited (Extended Data Fig. 3a and refs 2, [14] [15] [16] . Consistent with our data, a previous report has shown that the FTO obesity-associated region contains enhancers that drive Irx3-like expression in zebrafish 17 .
Our data suggest that the regulatory landscape of IRX3 spreads over megabase distances, whereas FTO expression is primarily regulated by regions proximal to its promoter. To test this, we engineered a human bacterial artificial chromosome (BAC) spanning 162 kb of the FTO locus, including its promoter and the 47-kb obesity-associated region (Extended Data Fig. 3 ). We recombineered a reporter cassette at the FTO translation start, and generated transgenic mice harbouring the engineered BAC. Transgenic mice expressed the reporter gene in multiple tissues, recapitulating the endogenous expression pattern of FTO 14 . We next determined that a 1.2-kb region corresponding to the FTO promoter is sufficient to recapitulate most of the FTO expression pattern (Extended Data Fig. 3 ). In contrast, a 2.8-kb region corresponding to the IRX3 promoter does not recapitulate any of the endogenous expression patterns of IRX3, suggesting that IRX3 expression relies on long-range cis-regulatory elements. A total of 15 human sequences in the broader FTO-IRX locus have been characterized as in vivo enhancers in mouse 17, 18 , driving reporter expression in Irx3-expressing tissues, including eye, limb, brain, neural tube and branchial arches 12, 19 ( Supplementary Table 2 ). Although these enhancers lie outside the obesity association interval, they are consistent with our chromatin looping data pointing to a broad Irx3 regulatory landscape, extending into Fto. Further supporting these findings, the genomic interval spanning FTO and IRX3 has been proposed to be part of a single genomic regulatory block, based on the presence of extended synteny across deep phylogenies and a high density of highly conserved noncoding elements 17 , as well as patterns of CTCF binding and chromatin interactions 20 . Under these models, our data support the idea that the broad expression patterns of FTO are primarily regulated by elements proximal to the promoter, and that IRX3 is endowed with an ancient, extensive cis-regulatory circuitry extending into FTO. Association with BMI (-log 10 (P)) 40 20 Figure 2 | BMI-associated SNPs are associated with expression of IRX3, but not FTO, in human brain. a, SNPs associated with BMI in the FTO locus. Forty-three SNPs associated with IRX3 expression (eSNPs) are shown in red, including 11 also associated with BMI. No SNPs are associated with FTO expression (P . 0.05). Thick arrowheads, IRX3 eSNPs outside the obesityassociated region (pink); thick arrow, rs9930506. b, In cerebellum, the allele of rs9930506 associated with increased BMI (risk allele) is correlated with increased IRX3 expression and not with FTO expression. Vertical middle bars represent the first and third quartiles, horizontal lines represent the median, and open circles denote outliers beyond 1.5 times the interquartile range. c, Histogram plotting the number of SNPs associated with IRX3 expression in adipose (black) and brain (red) (y axis) by the significance of their association with BMI (x axis). Full details of statistics are provided in the Methods.
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We next determined that gene expression studies in human brains corroborate our chromatin looping data, showing that the obesityassociated SNPs are associated with expression levels of IRX3, but not FTO. Our data and that of others 17 (Fig. 1b ) demonstrate that the obesityassociated SNPs overlap several in vivo enhancers, raising the possibility that allelic variants may disrupt enhancer activity and alter expression of their target gene(s). To test this, we carried out eQTL mapping in human brain samples. FTO and IRX3 are highly expressed in multiple regions of the brain including cerebellum and hypothalamus (Extended Data Fig. 4 ). Using a data set of 153 brain samples from individuals of European ancestry 21 , represented by cerebellum, we found significant association between 11 SNPs previously associated with increased body mass index (BMI), and expression of IRX3, but not FTO ( Fig. 2a and Supplementary Table 3 ). These common SNPs have minor allele frequencies ranging from 42.5 to 47.5% and are in strong linkage disequilibrium with each other (Extended Data Fig. 5 ). In all cases, such as for SNP rs9930506 (Fig. 2b) , the allele associated with increased BMI is also associated with increased IRX3 expression. Further analysis, using the GIANT Consortium data set of SNPs associated with BMI in 249,796 individuals 22 , reveals that among SNPs significantly associated with IRX3 expression in brain or adipose tissue, only those associated with IRX3 in brain show highly significant associations with BMI ( Fig. 2c ). Taken together, our data directly tie the noncoding genetic variation within FTO to tissuespecific modulation of IRX3, but not FTO, expression in human brain.
Next, we exploited animal models to determine a potential role for IRX3 expression in the regulation of BMI and/or metabolism. Mice homozygous for an Irx3-null allele (Irx3-knockout mice) are viable and fertile, with no evidence of embryonic lethality. We observed a 25-30% reduction of body weight in Irx3-knockout mice compared to control littermates (wild type), independent of gender ( Fig. 3a and Extended Data Figs 6a, b and 7a, b). This difference becomes more pronounced if animals were subjected to a high-fat diet (HFD), with Irx3-knockout animals showing no significant body weight gain, contrasting to a 63% increase in control animals ( Fig. 3a, b) . Importantly, the percentage of fat mass in Irx3-knockout mice was significantly reduced without marked change of the lean mass ratio (Fig. 3c, d and Extended Data Fig. 7c, d ). Irx3-knockout mice exhibit marked reduction in adiposity with smaller fat depots as well as reduced adipocyte size ( Fig. 3e and Extended Data Figs 6b-d and 7e, f). These results were confirmed by differential gene expression of adiposity markers (that is, leptin, adiponectin and mcp1) in the perigonadal white adipose tissue (PWAT) of Irx3-knockout mice (Extended Data Fig. 6e ). Importantly, Fto expression was not altered in the hypothalamus or PWAT of Irx3-knockout mice, suggesting that the lean phenotype of Irx3-knockout mice is not associated with Fto ( Fig. 3f ). As Irx3-knockout mice were resistant to HFD-induced obesity and metabolic disorder, such as hepatosteatosis ( Fig. 3e ), we examined glucose homeostasis by performing glucose tolerance tests (GTT) and insulin tolerance test (ITT) at different time points in the presence or absence of HFD. In 8-week-old mice, no difference in GTT was found ( Fig. 3g ). Although ageing and HFD led to glucose intolerance and insulin resistance in wild-type mice, Irx3knockout mice showed none of these metabolic phenotypes ( Fig. 3g -j).
Indirect calorimetric analysis showed higher energy expenditure in Irx3-knockout mice ( Fig. 3k and Extended Data Fig. 8a , b, e). Importantly, 
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Irx3-knockout mice show upregulation of brown adipocyte markers in PWAT, including Ucp1, Ppargc1a, Prdm16 and cidea, as well as increased expression of Adrb3 encoding the b3-adrenergic receptor, suggestive of elevated sympathetic activation ( Fig. 3l ). Furthermore, we found a significant increase of Ucp1 expression in the brown adipose tissue (BAT) of Irx3-knockout mice (Extended Data Fig. 8e , f). WAT predominantly stores excessive calories and its accumulation causes obesity, whereas brown adipose tissue dissipates energy (lipids and glucose) and has been the focus for potential development of novel therapeutic strategies to treat obesity and diabetes. Our data suggest that 'browning' of WAT by higher sympathetic tone and activation of BAT might lead to increased energy expenditure in Irx3-knockout mice and partially account for their leanness and protection from diet-induced obesity. Browning of WAT by increased sympathetic activity is a phenomenon controlled by hypothalamic circuits integrating central and peripheral metabolism regulation. Our human eQTL data suggest that the obesity-associated SNPs are associated with IRX3 expression in brain. We determined that Irx3 is expressed in the arcuate nucleus and median eminence of the hypothalamus, two critical regions involved in the regulation of energy homeostasis (Fig. 3m) 23, 24 . To investigate a possible role of Irx3 expression in the hypothalamus mediating the body composition and energy homeostasis phenotypes in Irx3-knockout mice, we used Rosa26 EnR-Irx3 conditional transgenic mice expressing a dominant negative form of Irx3 (EnR-Irx3) by crossing with Ins2-Cre (Extended Data Fig. 9a, b) 23, 25 . This design allows for disrupting Irx3 function while preserving the architecture of genomic interactions between the Irx3 promoter and long-range regulatory sequences including the Fto obesity-associated region. Interestingly, EnR-Irx3;Ins2-Cre mice phenocopy the physiological, histological, and molecular metabolism phenotypes of germline Irx3-knockout mice (Fig. 4a-d and Extended Data Fig. 9c, d) . Energy expenditure was significantly higher in EnR-Irx3;Ins2-Cre mice with similar food intake and locomotor activity ( Fig. 4e and Extended Data Fig. 10a-e ). Notably, these mice also showed 'browning' of WAT as well as activation of BAT ( Fig. 4f and Extended Data Fig. 10f, g) . Together, our data support the notion that the hypothalamic expression of Irx3 regulates energy homeostasis and body composition.
Our results do not dispute the idea emerging from animal models that Fto is also a regulator of body mass and composition. The functional link between FTO and body mass regulation originated from animal models, unequivocally demonstrating that variation in FTO expression results in variation in body mass phenotypes. But to assess the null expectation that genetic manipulations in mice may result in variation in these parameters, we searched among 7,556 targeted mouse gene knockout models for evidence of alterations in body size, mass and growth (see Methods). Nearly one-third (2,166; 29%) of gene knockouts in mice show alteration of these phenotypes, underscoring that animal models alone are not sufficient to definitively establish a functional relationship between a given gene and long-range noncoding variants ( Supplementary Table 4 ). It is the aggregate of our data on chromatin looping, patterns of in vivo enhancer function, human eQTL mapping and mouse model data that collectively place IRX3 as an important target gene of the genetic association with human obesity. These observations have direct implications for how to interpret the associations characterized for thousands of noncoding variants with human disease and related quantitative traits. We observe more than 150 genomic regulatory blocks, similar to that containing FTO and IRX3, overlapping with noncoding SNPs associated with human disease and complex traits in GWAS (Methods and Supplementary Table 5 ), highlighting the need for a careful experimental pipeline to define the target gene(s) for each disease-associated noncoding SNP.
Our data posit that the obesity-associated SNPs within FTO are functionally connected with regulation of IRX3 expression, and that IRX3 is an important determinant of body mass and composition. IRX3 encodes a transcription factor highly expressed in brain. Although our data represent the first demonstration of the intersection of IRX3 biology with body mass composition and metabolism, previous work identified IRX3 overexpression in adipocytes as a hallmark of the molecular switch seen in patients after profound weight loss following bariatric surgery 26 . These data indicate that IRX3 may have important roles regulating metabolism beyond the ones we describe associated with Irx3 expression in hypothalamus. Future investigations will determine the precise molecular mechanisms by which IRX3 regulates metabolic parameters.
METHODS SUMMARY
For 4C-seq, chromatin was digested with DpnII and Csp6I. Captured DNA was amplified using promoter-specific primers and deep sequenced.
For 3C, nuclei were digested with HindIII. Primer quality was assessed using serial dilutions of BACs encompassing the regions of interest (RP23-268O10, RP23-96F3). The average of four independent experiments is represented graphically (Extended Data Fig. 2c ).
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS 3C assays. 3C assays were performed as described in ref. 27 . Mouse brain tissue was processed to get single cells samples. Ten-million isolated cells were treated with lysis buffer (10 mM Tris-HCl, pH 8, 10 mM NaCl, 0.3% IGEPAL CA-630 (Sigma-Aldrich, I8896), 1X protease inhibitor cocktail (cOmplete, Roche, 11697498001)) and nuclei were digested with HindIII endonuclease (Roche, 10798983001). Subsequently, DNA was ligated with T4 DNA ligase (Promega, M1804). A set of locus specific primers (see table) was designed with the online program primer3 v. 0.4.0 (ref. 28) , each one close to a HindIII restriction site. These primers were used to make real-time quantitative PCRs using a BioRad CFX96 Real Time System with SsoFast EvaGreen Supermix (BioRad 172-5203), in order to measure the relative enrichment in each ligation product. The primer designed within the linkage disequilibrium-block was used as fixed primer. The quality of all primer pairs was measured using serial dilutions of a bacterial artificial chromosome (BAC) DNA that encompass the regions of interest (RP23-268O10, RP23-96F3). PCR values were normalized by means of control primers designed in the Ercc3 gene locus. The average of four independent experiments is represented graphically (Extended Data Fig. 2c ). 4C-seq. 4C-seq assays were performed as previously reported 27, [29] [30] [31] . Whole embryos (9.5 days of development) or whole adult (8 weeks) mice brains (both strain CD-1; Charles River) were processed to get approximately 10-million isolated cells, which were treated with lysis buffer ( In brief, raw sequencing data were de-multiplexed and aligned using either the Mouse July 2007 (NCBI37/mm9) or Zebrafish December 2008 (Zv8/danRer6) assembly as the reference genome. Reads located in fragments flanked by two restriction sites of the same enzyme, or in fragments smaller than 40 bp were filtered out. Mapped reads were then converted to reads-per-1kb-bin units, and smoothed using a running mean 5-fragment window algorithm. To calculate the statistically significant targets for each viewpoint, a background theoretical model was calculated as the exponential fit curve of the average signal of 61 4C-seq different samples 11, 33, 34 . The P value for each bin was calculated by means of Poisson probability function. Smoothed data were uploaded to the UCSC Browser 35 for visualization and plotted using the browser and Circos 36 . For plotting, statistically significant targets were defined as P , 0.01. Primers used for 3C experiments. The following primers were used for 3C experiments: '3c_mouse_LDBlock', 59-TGGTCTCGGGTATCTTGTCC-39; '3c_ mouse_Irx3_control1', 59-TCGCTCCTAGTGAGACTTTC-39; '3c_mouse_Irx3_ promoter', 59-TGATGTTGGTTCCTTACTAGG-39; '3c_mouse_Irx3_control2', 59-TCCACAGAAACATCTGACG-39; '3c_mouse_Ercc3-1', 59-TGACCTCCAC ACTCCTGAC-39; '3c_mouse_Ercc3-2', 59-ATGCGCAATTAGAAACTGC-39. Primers used for 4C-seq experiments. The following primers were used for 4Cseq experiments: '4c_mouse_Fto_read', 59-AATGATACGGCGACCACCGAAC ACTCTTTCCCTACACGACGCTCTTCC GATCTCATATTGCTCTGGATGCA GATC-39; '4c_mouse_Fto_noread', 59-CAAGCAGAAGACGGCATACGAGAA CTACCCTTCCCAGAATGC-39; '4c_mouse_Irx3_read', 59-AATGATACGGCG ACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGAT CTCCGCCGC GGAGCAGATC-39; '4c_mouse_Irx3_noread', 59-CAAGCAGAAGACGGCAT ACGATGGAGTCGCCAATCACC-39; '4c_zebrafish_Fto_read', 59-AATGATAC GGCGACCACCGAACACTCTTTCCCTACACGACGCTCTTCCGAT CTCCT CCACTGTCATCCGATC-39; '4c_zebrafish_Fto_noread', 59-CAAGCAGAAGA CGGCATACGACTACATTTTATGTCAGTTTCGGG-39; '4c_zebrafish_Irx3a_read', 59-AATGATACGGCGACCACCGAACACTCTTTCCCTACACGACGCTCTT CCGAT CTCCTACCGGATTACTCTACAGATC-39; '4c_zebrafish_Irx3a_noread', 59-CAAGCAGAAGACGGCATACGAAAAACGCCCAGAAGACTGAC-39. ENCODE ChIA-PET. Publicly available data for the breast cancer MCF7 cell line, generated as part of the ENCODE project 37 , were downloaded from and visualized with the WashU EpiGenome Browser 38 (http://epigenomegateway.wustl.edu/browser/). ChIA-PET has been performed to capture long-range chromatin interactions associated with RNA polymerase II 39 .
Locus conservation. To assess the level of high-level conservation of the FTO-IRX5 locus, we used phastCons 40 elements and scores as a measurement of conservation.
High-scoring phastCons elements (LOD . 680, top 1%) cover 3% (38,040 out of 1,244,409 bp) of the genomic space that includes FTO and IRX5 (hg19, chromsome 16: 53,731,249-54,975,288), whereas on average, only 0.5 6 0.6% of genomic intervals with the same length are occupied by such high-scoring phastCons elements. Genomic intervals of the same size of the FTO-IRX3 locus were generated every 10 kb for each chromosome. The FTO-IRX5 is at the top 1% intervals containing high-scoring phastCons elements.
Similarly, in the FTO-IRX5 interval, 9% of the base pairs have phastCons score above 0.9 (range: 0.0-1.0), whereas 14,164 intervals from all chromosomes of the same size offset by 200 kb contain only 3.8% 6 1.9 of such high-scoring base pairs. At 9%, the FTO-IRX5 is at the top 2% intervals with the most conserved base pairs.
These results indicate that the FTO-IRX5 interval contains significantly more highly conserved base pairs than most genomic loci. Mouse in vivo transgenic reporter assays. Enhancer reporter assays and constructs, including the modified BAC, were created as reported previously 41 Mouse in vivo transgenic reporter assays were performed as reported previously 41 . In situ hybridization assays were performed according to standard protocols 42 . The full-length mouse Fto coding DNA sequence (CDS) as riboprobe template was from IMAGE clone 5708558 (ATCC). Gene expression in human tissues. For the eQTL analyses, we used cerebellum 21 (n 5 153; publicly available in GEO under accession number GSE35974) and adipose 43 (n 5 62; publicly available in GEO under accession number GSE40234); details of the samples, the quality control procedure and the normalization approach used were described previously 21 . For adipose, the samples were chosen to be at the tails of the distribution of insulin sensitivity matched on age, gender and natural log of BMI. Because the adipose samples included individuals of African ancestry, we performed principal component analysis and tested each marker in the locus for the additive effect of allele dosage on the residual expression phenotype (IRX3 and FTO) after adjusting for the principal components (n 5 2). Similarly, for cerebellum, we performed linear regression on the residual expression phenotype (IRX3 and FTO) after adjusting for sex and pH to evaluate the additive effect of allele dosage at each marker in the locus; the non-diseased samples (obtained from the Stanley Medical Research Institute) included in the analysis were of European descent and thus the principal components were not used to generate the residual expression. Significance (P value) was evaluated using the t-statistic from the regression. Single nucleotide polymorphisms associated with gene expression levels. We downloaded genome-wide association data from the Genetic Investigation of Anthropometric Traits 22 (GIANT) Consortium website (http://www.broadinstitute. org/collaboration/giant/index.php/GIANT_consortium_data_files#BMI_.28down load_GZIP.29). We extracted the P values for those SNPs in the locus with significant association (P , 0.05) with IRX3 or FTO expression in adipose or cerebellum. We plotted the distribution of association P values for these expression-associated SNPs (eSNPs). rs9930506 is highly associated with BMI (P 5 1.41 3 10 253 , n 5 123541). Recombination rates are estimated from the International HapMap Project. Statistical analyses. Statistical analyses were carried out using the R statistical software (http://cran.r-project.org/). Regional plots were done by repurposing an R script retrieved from the Broad Institute (http://www.broadinstitute.org/diabetes/ scandinavs/figures.html). Mice. All animal experimental protocols approved by the Animal Care Committee of the Toronto Centre of Phenogenomics conformed to the standards of the Canadian Council on Animal Care. Irx3-deficient (Irx3-knockout) mice 44 and Ins2-Cre mice 23 were described previously. Rosa26 EnR-Irx3 conditional transgenic mice (EnR-Irx3) were generated using pROSA26PA gene-targeting vector as described previously 45 . Mice were maintained on 12-h light-dark cycles and provided with food and water ad libitum. For diet-induced obesity studies, 8-week-old male mice were subjected to 45% high-fat diet (Research Diets) for 10 weeks. Body weight was measured every week from 4 to 18 weeks of age, and body composition was analysed using an EchoMRI device (Echo Medical Systems) at 18 weeks of age. Body mass index (BMI) was calculated by dividing body weight (g) by body length (mm) squared (BMI 5 body weight/body length 2 ). Metabolic phenotyping experiments. Energy expenditure was evaluated through indirect calorimetry (Oxymax System, Columbus Instruments) over periods of 24 h.
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In brief, energy expenditure was calculated by multiplying oxygen consumption (VO 2 ) by the calorific value (CV 5 3.815 1 1.232 3 respiratory exchange ratio) and corrected by lean mass. Locomotor activity and food intake were also measured simultaneously. For glucose and insulin tolerance tests, mice were subjected to intraperitoneal bolus injection of glucose (1 mg g 21 of body weight) or insulin (1.5 milli-units per g) after fasting for overnight (14 to 16 h) or 6 h with water ad libitum, respectively. Blood glucose levels were measured at the indicated intervals. For histological analysis, tissues were fixed in 4% paraformaldehyde and embedded in paraffin. Sections of 5 mm were stained with haematoxylin and eosin (H&E). Irx3 expression in brain and lung was examined using Irx3 lacZ knock-in mice with b-galactosidase staining. Gene and protein expression analyses. Total RNA was extracted from fat tissues or hypothalamus using RNeasy Lipid Tissue Kit (Qiagen), and complementary DNA was synthesized from 2 mg of RNA using M-MLV reverse transcriptase (Invitrogen) with oligo(dT). Gene expression assay was conducted using SYBR Green methods on Viia7 (Applied Biosystems), and relative cycle threshold (CT) values were normalized by b-actin. Primer sequences are available upon request. Western blot analysis was performed as described previously 46 . The same amount of protein extracted from hypothalamus or brown adipose tissues was loaded, which was confirmed by b-actin as a loading control. Antibodies used are as follows: Ucp1 (Santa Cruz Biotechnology), Irx3 (generated in-house) and b-actin (Calbiochem). Statistics. All results are expressed as mean 6 s.e.m. Statistical significance of differences among groups was determined by Student's t-test or analysis of variance (ANOVA) with post-hoc analysis, Student-Newman-Keuls using Sigma Stat (SPSS). Differences at P , 0.05 were considered statistically significant (*P , 0.05 versus WT or control; {P , 0.05 versus WT, HFD). The following numbers of mice per sample were used for comparison; body-weight measurement for Irx3 mice (ND, WT/knockout (KO), n 5 32/25; HFD, WT/KO, n 5 12/7) and EnR-Irx3 mice (control/mutant, n 5 9/12); body composition analysis for Irx3 mice (ND WT/KO, n 5 21/12; HFD WT/KO, n 5 8/5) and EnR-Irx3 mice (control/mutant, n 5 9/12); glucose tolerance test for Irx3 mice (ND 8 weeks, WT/KO, n 5 8/5; ND 18 weeks, WT/KO, n 5 10/6; HFD 18 weeks, WT/KO, n 5 12/7) and EnR-Irx3 mice (control/mutant, n 5 5/8); insulin tolerance test for Irx3 mice (WT/KO, n 5 12/7); indirect calorimeter analysis for Irx3 mice(ND WT/KO, n 5 7/5; HFD WT/KO, n 5 8/4) and EnR-Irx3 mice (control/mutant, n 5 5/7), and gene expression analysis for Irx3 mice (WT/KO, n 5 10/7) and EnR-Irx3 mice (control/ mutant, n 5 5/7). Mouse body-mass phenotypes. To calculate the fraction of knockout mice that display a phenotype affecting body mass, we consulted the Mouse Genome Informatics (MGI) database 47 .
First, to determine the number of gene knockouts that result in a body mass phenotype, we needed to define a more precise phenotype. The Mammalian Phenotype Ontology 48 (http://www.informatics.jax.org/searches/MP_form.shtml) specifies a controlled vocabulary by which all mice in the MGI database are classified. Within this framework, (we believe) the most applicable is 'abnormal postnatal growth/weight/body size' (MP:0002089).
Next, we crafted a query using the MouseMine portal 49 (http://www.mousemine. org) to access the MGI database, using MP:0002089 as the search criteria in the 'Mammalian phenotypes R Mouse genotypes' template (http://www.mousemine. org/mousemine/template.do?name5MPhenotype_MFeature&scope5all). We asked for all targeted alleles on chromosomes 1-19, X and Y, reasoning that many nontargeted (that is, random, chemical and radiation-induced) mutations have not been precisely mapped, making it difficult if not impossible to ensure that they are not counted multiple times. Also, in the context of our study, we are discussing the chance that a targeted knockout would give a specific phenotype, so these types of alleles are most relevant. Finally, we excluded alleles present only as cell lines, which left 2,166 unique genes.
To determine the total number of targeted mutations present in the MGI database, we performed a search identical to that above but omitting the MP:0002089 term, which left 7,556 unique genes. Genomic regulatory blocks. Genomic regulatory blocks are regions under strong selection that contain a number of syntenic highly conserved sequences, believed to regulate a syntenic target gene ('anchor gene', the gene that is the raison d'être of the GRB). There are different approaches to determine GRBs, usually identifying syntenic genes and non-coding conserved regions that span a region and determining the boundaries of the region.
GWAS identified SNPs that might affect noncoding regulatory elements that, in turn, regulate specific target genes. Assignment of regulatory elements to targets is still a challenge, the simplest method being to assign them to the nearest gene. In the case of FTO, because the GWAS SNP occurs in an FTO intron, this gene was considered to be the target.
The idea put forward here is that when regulatory elements occur within a GRB, which is the case for FTO, IRX3 and IRX5, it is likely that they target the anchor gene (IRX3 or IRX5), given its importance. Supplementary Table 5 contains an annotation of GRBs and their anchor genes, and the GWAS SNPs within the GRB, as well as annotation of whether the nearest gene is the anchor gene or not. In those cases in which the nearest gene differs from the anchor gene, we propose that the anchor gene be used as the putative target and additional experimentation as shown in this work should be performed to determine precisely which is the target gene for the GWAS-affected regulatory element.
Genomic regulatory blocks were obtained from UCNEbase (http://ccg.vital-it. ch/UCNEbase/) 50 . Human UCNE clusters (hg19) were downloaded from http:// ccg.vital-it.ch/UCNEbase/data/download/clusters/hg19_clusters_coord.bed and are referred here as GRBs.
The hg19 GWAS catalogue from the UCSC Genome Browser was downloaded and the tagging SNPs contained in GRBs with more than one gene (making SNP assigning doubtful) were kept for further annotation. SNPs occurring in exons were removed. The nearest gene was considered to be the RefSeq gene whose transcription start site was the nearest, or the gene where the SNP is contained.
Extended Data Figure 3 | Gene expression in mouse tissue. a, FTO
expression in lung and brain, shown by RNA in situ hybridization for mouse Fto mRNA, in newborn (P1) mouse. Lungs and heart (left, whole organs) were processed simultaneously and in the same well as brain (right, sagittal section) so that the relatively higher expression in brain can be observed. b, LacZ staining for b-galactosidase expression driven from the human FTO promoter. Top, the promoter-LacZ fusion is in the context of 162-kb of human genomic sequence carried in a BAC containing the first three exons of FTO, the entire obesity-associated interval and any enhancers present. The broad expression is consistent with previous reports in human and mouse (see main text for references). At bottom, the promoter-LacZ construct is isolated: only the 1,237 bp proximal to the transcriptional start site are included. Broad expression is recapitulated, indicating the robust transcriptional competency of the human FTO promoter. c, In contrast, the 2,820-bp proximal human IRX3 promoter is not sufficient to drive LacZ expression, which is consistent with an enhancer-dependent transcriptional control mechanism.
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